Business
Concepta signs agreement with Selective Antibodies
Concepta signs agreement with Selective Antibodies.
About this update from Fortis Frontier Plc
[{"type":"text","content":"\n \nRNS Number : 1690W Concepta PLC 07 February 2017 \n\n7 February 2017\n \nConcepta plc (\"Concepta\" or the \"Company\")\n \nConcepta signs technology transfer and licence agreement with Selective Antibodies to develop stress test for myLotus fertility product\n \nConcepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed a technology transfer and licence agreement (\"Agreement\") with Selective Antibodies Ltd, a UK based diagnostics company (\"Selective Antibodies\"), for the development of a stress test. This is part of the Company's new product development for its proprietary myLotus home self-testing platform that helps women with unexplained infertility* to conceive. This is in line with the strategy set out at the time of the Company's admission to AIM In 2016. \n \nUnder the Agreement, Concepta will, inter alia, be granted the rights to intellectual property (\"IP\") developed by Selective Antibodies, comprising licensed patents and associated knowhow, for the measurement of small molecules in bodily fluids.\n \nThe key terms of the Agreement include:\n· Cost - Concepta will pay Selective Antibodies for the development of the test and for technology transfer, plus a royalty based on sales of products developed using the IP. Work on the product development will start on 1st March 2017\n· Terms of agreement - subject to fulfilment of obligations on each party, up until the date 5 years beyond the expiry of the patents to which the IP relates\n \nThis will be used to expand Concepta's existing myLotus platform capabilities (which includes measurements of a woman's personal hCG and LH hormone levels), enabling users to also monitor stress through quantitative measurement of their levels of stress hormones of which cortisol is the key one. Stress is a common cause of several health conditions and is widely recognised as a key factor, which can significantly impact both male and female fertility factors.\n \nErik Henau, CEO of Concepta commented: \"Concepta's key differentiator in the mobile health and personalised healthcare sector has been to develop a platform that grants users the ability to quantify...